Terlipressin in the management of liver disease

References

• New recommendations for terlipressin-containing medicines in the treatment of hepatorenal syndrome European Medicines Agency 2022. Available from: https://www.ema.europa.eu/en/news/new-recommendations-terlipressin-containing-medicines-treatment-hepatorenal-syndrome
   Google Scholar
• Belcher JM, Parada XV, Simonetto DA, et al. Terlipressin And the treatment of hepatorenal syndrome: how the CONFIRM trial moves the story forward. Am J Kidney Dis. 2022 May;79(5):737–745. doi: 10.1053/j.ajkd.2021.08.016
   PubMed Web of Science ®Google Scholar
• Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014–1048. doi: 10.1002/hep.31884
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Boyer TD, Frederick RT, et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017 Jun;45(11):1390–1402. doi: 10.1111/apt.14052
   PubMed Web of Science ®Google Scholar
• Gupta K, Bhurwal A, Law C, et al. Acute kidney injury and hepatorenal syndrome in cirrhosis. World J Gastroenterol. 2021 Jul 14;27(26):3984–4003. doi: 10.3748/wjg.v27.i26.3984
   PubMed Web of Science ®Google Scholar
• Carrion AF, Martin P. Renal dysfunction in cirrhotic patients. Am J Gastroenterol. 2019 Sep;114(9):1407–1410. doi: 10.14309/ajg.0000000000000355
   PubMed Web of Science ®Google Scholar
• Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therapy Adv Gastroenterol. 2022;15:17562848221102679. doi: 10.1177/17562848221102679
   Web of Science ®Google Scholar
• Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996 Jan;23(1):164–176. doi: 10.1002/hep.510230122
   PubMed Web of Science ®Google Scholar
• Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007 Sep;56(9):1310–1318. doi: 10.1136/gut.2006.107789
   PubMed Web of Science ®Google Scholar
• Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015 Apr;62(4):968–974. doi: 10.1016/j.jhep.2014.12.029
   PubMed Web of Science ®Google Scholar
• Patidar KR, Piano S, Cullaro G, et al. Recent advances in the management of hepatorenal syndrome: a US perspective. Clin Gastroenterol Hepatol. 2023 Apr;21(4):897–901.e1. doi: 10.1016/j.cgh.2022.12.034
   PubMed Web of Science ®Google Scholar
• Angeli P, Bernardi M, Villanueva C. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406–460. doi: 10.1016/j.jhep.2018.03.024
   PubMed Web of Science ®Google Scholar
• Garcia‐Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310–335. doi: 10.1002/hep.28906
   PubMed Web of Science ®Google Scholar
• Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015 Aug;62(2):567–574. doi: 10.1002/hep.27709
   PubMed Web of Science ®Google Scholar
• Møller S, Hansen EF, Becker U, et al. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver. 2000;20(1):51–59. doi: 10.1034/j.1600-0676.2000.020001051.x
   PubMedGoogle Scholar
• Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother. 2006 Dec 01;40(12):2170–2177.
   PubMed Web of Science ®Google Scholar
• Kulkarni AV, Arab JP, Premkumar M, et al. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int. 2020 Dec;40(12):2888–2905. doi: 10.1111/liv.14703
   PubMed Web of Science ®Google Scholar
• Inc. MHP. Terlivaz (Terlipressin). United States Food and Drug Administration. 2022.
   Google Scholar
• Nadim MK, Garcia-Tsao G, Hardin CC. Acute kidney injury in patients with cirrhosis. N Engl J Med. 2023;388(8):733–745. doi: 10.1056/NEJMra2215289
   PubMed Web of Science ®Google Scholar
• Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016 Mar;63(3):983–992. doi: 10.1002/hep.28396
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008 May;134(5):1360–1368. doi: 10.1053/j.gastro.2008.02.014
   PubMed Web of Science ®Google Scholar
• Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016 Jun;150(7):1579–1589.e2. doi: 10.1053/j.gastro.2016.02.026
   PubMed Web of Science ®Google Scholar
• Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021 Mar 4;384(9):818–828. doi: 10.1056/NEJMoa2008290
   PubMed Web of Science ®Google Scholar
• Jamil K, Weinberg E, Reddy R. S1173 terlipressin treatment of patients with hepatorenal syndrome type 1 decreased the need for renal replacement therapy in transplant recipients: a 12-month follow-up of the CONFIRM Study. Off J Am Coll Gastroenterol ACG. 2022;117(10S):e853. doi: 10.14309/01.ajg.0000861332.82608.85
   Google Scholar
• Curry MP, Vargas HE, Befeler AS, et al. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies. Hepatol Commun. 2023;7(1):e1307–e1307. doi: 10.1097/01.HC9.0000897228.91307.0c
   PubMed Web of Science ®Google Scholar
• Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011 Aug;55(2):315–321. doi: 10.1016/j.jhep.2010.11.020
   PubMed Web of Science ®Google Scholar
• Piano S, Schmidt HH, Ariza X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome. Clin Gastroenterol Hepatol. 2018 Nov;16(11):1792–1800.e3. doi: 10.1016/j.cgh.2018.01.035
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Henrique Pereira G, Solà E, et al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transpl. 2015;21(11):1347–1354. doi: 10.1002/lt.24210
   PubMed Web of Science ®Google Scholar
• Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012 Jun;56(6):1293–1298. doi: 10.1016/j.jhep.2012.01.012
   PubMed Web of Science ®Google Scholar
• Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020 Feb;71(2):600–610. doi: 10.1002/hep.30208
   PubMed Web of Science ®Google Scholar
• Singh V, Jayachandran A, De A, et al. Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion: A randomized trial. Indian J Gastroenterol. 2023 May 5;42(3):388–395. doi: 10.1007/s12664-023-01356-6
   PubMed Web of Science ®Google Scholar
• Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology. 2002 Apr 01;122(4):923–930.
   PubMed Web of Science ®Google Scholar
• Singal AK, Jalan R. Terlipressin for hepatorenal syndrome: opportunities and challenges. Lancet Gastroenterol Hepatol. 2023;8(2):104–106. doi: 10.1016/S2468-1253(22)00377-6
   PubMed Web of Science ®Google Scholar
• Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther. 2012 Jun;35(11):1267–1278. doi: 10.1111/j.1365-2036.2012.05088.x
   PubMed Web of Science ®Google Scholar
• Walker S, Kreichgauer H-P, Bode JC. Terlipressin vs. Somatostatin in bleeding esophageal varices: A controlled, double-blind study. Hepatology. 1992;15(6):1023–1030. doi: 10.1002/hep.1840150609
   PubMed Web of Science ®Google Scholar
• Abid S, Jafri W, Hamid S, et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol. 2009 Mar;104(3):617–623. doi: 10.1038/ajg.2008.147
   PubMed Web of Science ®Google Scholar
• Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014;60(3):954–963. doi: 10.1002/hep.27006
   PubMed Web of Science ®Google Scholar
• Sridharan K, Sivaramakrishnan G. Vasoactive agents for the management of variceal bleeding: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. Drug Res (Stuttg). 2019 Aug 20;69(9):487–495.
   PubMed Web of Science ®Google Scholar
• Arora V, Choudhary SP, Maiwall R, et al. Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding. Hepatol Int. 2023 Feb;17(1):131–138. doi: 10.1007/s12072-022-10416-6
   PubMed Web of Science ®Google Scholar
• Bai Z, An Y, Guo X, et al. Role of terlipressin in cirrhotic patients with ascites and without hepatorenal syndrome: a systematic review of current evidence. Can J Gastroenterol Hepatol. 2020;2020:5106958. doi: 10.1155/2020/5106958
   PubMed Web of Science ®Google Scholar
• Krag A, Møller S, Henriksen JH, et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007 Dec;46(6):1863–1871. doi: 10.1002/hep.21901
   PubMed Web of Science ®Google Scholar
• Xing F, Li S, Zhang JJ, et al. Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites. Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):982–988. doi: 10.3760/cma.j.issn.1007-3418.2019.12.010
   PubMedGoogle Scholar
• Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut. 2002 Jan;50(1):90–94. doi: 10.1136/gut.50.1.90
   PubMed Web of Science ®Google Scholar
• Taneja S, Chawla YK. Perioperative use of terlipressin in adult liver transplant. Liver Transpl. 2017;23(8):995–996. doi: 10.1002/lt.24800
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Hasanin A, Allah SA, et al. The haemodynamic effects of the perioperative terlipressin infusion in living donor liver transplantation: A randomised controlled study. Indian J Anaesth. 2015 Mar;59(3):156–164. doi: 10.4103/0019-5049.153037
   PubMedGoogle Scholar
• Kulkarni AV, Kumar K, Candia R, et al. Prophylactic perioperative terlipressin therapy for preventing acute kidney injury in living donor liver transplant recipients: a systematic review and meta-analysis. J Clin Exp Hepatol. 2022 Mar;12(2):417–427. doi: 10.1016/j.jceh.2021.06.019
   PubMed Web of Science ®Google Scholar
• Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit Care Med. 2011 Jun;39(6):1329–1334. doi: 10.1097/CCM.0b013e3182120842
   PubMed Web of Science ®Google Scholar
• Chapman B, Gow P, Sinclair M, et al. Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant. JHEP Rep. 2019 Aug;1(2):107–113. doi: 10.1016/j.jhepr.2019.05.002
   PubMedGoogle Scholar
• Yim SY, Seo YS, Jung CH, et al. Risk factors for developing hyponatremia during terlipressin treatment: a retrospective analyses in variceal bleeding. J Clin Gastroenterol. 2015;49(7):607–612. doi: 10.1097/MCG.0000000000000217
   PubMed Web of Science ®Google Scholar
• Chung SH, Jun DW, Kim KT, et al. Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. Dig Dis Sci. 2010 Apr;55(4):1135–1141. doi: 10.1007/s10620-009-0829-x
   PubMed Web of Science ®Google Scholar
• Pan X, Zhou Z, Jin X, et al. Clinical characteristics and risk factors of severe hyponatremia in cirrhotic patients treated with terlipressin. J Clin Pharm Ther. 2020 Feb;45(1):191–198. doi: 10.1111/jcpt.13057
   PubMed Web of Science ®Google Scholar
• McClure T, Chapman B, Hey P, et al. Long-term continuous terlipressin infusion in cirrhotic patients with hepatorenal syndrome or refractory ascites awaiting liver transplantation is associated with an increase in plasma sodium. United Eur Gastroenterol J. 2019 Nov;7(9):1271–1273. doi: 10.1177/2050640619878996
   PubMed Web of Science ®Google Scholar
• Information NCfB. PubChem compound summary for CID 72081, terlipressin. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Terlipressin
   Google Scholar